(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has accepted Mr. Albert Beraldo’s resignation as director of the Company and Audit Committee Chair, effective July 14, 2017.
- 0 Comments
- FY2017